Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846)
Phase 3
Completed
- Conditions
- SchizophreniaSchizoaffective Disorder
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 440
- Registration Number
- NCT00212771
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
Phase 3
Completed
- Conditions
- SchizophreniaSchizoaffective Disorder
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1225
- Registration Number
- NCT00212784
Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817)
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 481
- Registration Number
- NCT00212836
IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)
Phase 3
Completed
- Conditions
- HypercholesterolemiaMyocardial Infarction
- Interventions
- Drug: ezetimibe/simvastatinDrug: simvastatinDrug: Placebo for simvastatin 40 mgDrug: Placebo for ezetimibe 10 mg/simvastatin 40 mg combination
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 18144
- Registration Number
- NCT00202878
Effectiveness and Safety of Ezetimibe Added to Atorvastatin in Patients With High Cholesterol and Coronary Heart Disease (Study P03740)
Phase 4
Completed
- Conditions
- HypercholesterolemiaCoronary Heart Disease
- Interventions
- Drug: placeboDrug: ezetimibe
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 81
- Registration Number
- NCT00202904
6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 196
- Registration Number
- NCT00174265
Ezetimibe Plus (+) Simvastatin Versus Atorvastatin Comparative Study (0653A-092)(COMPLETED)
Phase 4
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 203
- Registration Number
- NCT00166504
EASEGO Study: Doubling of Atorvastatin/Simvastatin or INEGY in Patients With Hypercholesterolemia and Coronary Artery Disease(CAD)(0653A-089)
Phase 4
Completed
- Conditions
- Atherosclerosis
- Interventions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 367
- Registration Number
- NCT00166530
Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Control (41513)(COMPLETED)(P05785)
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 187
- Registration Number
- NCT00156065
Long-Term Efficacy and Safety of Asenapine Using Olanzapine as a Positive Control (41512)(COMPLETED)(P05784)
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 260
- Registration Number
- NCT00156091
© Copyright 2025. All Rights Reserved by MedPath